Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: day (1000), time (1000)

RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RCVP) Regimen Lymphoma – RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Indication Non-Hodgkin’s Lymphoma Toxicity
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

RCHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (21) Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (21) (RCHOP 21) There are multiple versions of this protocol in use. Please
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP21-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-21-Ver-1.2.pdf

RCEOP-Cyclophosphamide-Etoposide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE Regimen (RCEOP) Lymphoma – RCEOP-Cyclophosphamide-Etoposide-Prednisolone-RituximabVincristine Indication Non Hodgkin’s Lymphoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCEOP-Cyclophosphamide-Etoposide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

Pembrolizumab_400mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (400mg) Regimen • Lymphoma – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Pembrolizumab (200mg) Regimen • Lymphoma – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for relapsed or refractory classical Hodgkin lymphoma in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Pembrolizumab-200mg.pdf

BEACOPP escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP Escalated) Regimen • Lymphoma – BEACOPP Escalated -Bleomycin-Cyclophosphamide-DoxorubicinEtoposide-Prednisolone-Procarbazine-Vincristine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-escalated.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomib (weekly) with daratumumab and dexamethasone Indication • Daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

MelanomaBleomycinECT

Description: ChemotherapApril 17y Protocol SKIN CANCER BLEOMYCIN (ELECTROCHEMOTHERAPY) Please note this protocol only refers to the administration of bleomycin in the setting
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/MelanomaBleomycinECT.pdf

CladribineSC

Description: Chemotherapy Protocol HAIRY CELL LEUKEMIA CLADRIBINE (SC) Regimen • HCL – Cladribine (SC) Indication • Hairy cell leukemia Toxicity Drug Cladribine Adverse Effect Skin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/CladribineSC.pdf

CladribineIV

Description: Chemotherapy Protocol HAIRY CELL LEUKEMIA CLADRIBINE (IV-5 day) Regimen • HCL – Cladribine (IV-5 day) Indication • Hairy cell leukaemia (this is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/CladribineIV.pdf

471 to 480 of 985

Previous … 46 47 48 49 50 … Next